FDA Orphan Disease Clinical Trial Grants Aim To Reduce Financial Risk
Executive Summary
Agency awards $22m to support 15 clinical trials and approximately $10m for six natural history studies in rare diseases. FDA Commissioner Gottlieb highlights the program as a way for the agency to help de-risk clinical development.
You may also be interested in...
Rare Diseases: Growing Understanding Will Unlock Accelerated Approval, FDA Says
US FDA officials say they need knowledge of the disease to have the confidence to use accelerated approval.
Keytruda's New Tissue-Agnostic Indication Could Prompt Orphan Policy Changes
US FDA contemplating how to match orphan designation process with drug development moving to molecularly-targeted therapies.
RSV Vaccine May Be On Market In 2023, CDC’s ACIP Anticipates
Panel expects to review five respiratory syncytial virus vaccines and vote on one or two of them in June 2023 and others four months later. Sanofi presents results of three clinical trials of its monoclonal antibody nirsevimab, which is on track to be the second RSV prophylaxis for infants.